Progentec concludes series A funding round with USD 5m.
M2 EQUITYBITES-January 13, 2020-Progentec concludes series A funding round with USD 5m
(C)2020 M2 COMMUNICATIONS http://www.m2.com
Progentec, a developer of nextgen diagnostics and digital therapeutics for the management of autoimmune diseases, has announced that it has completed a USD 5 million Series A funding round led by Plains Venture Partners, the Oklahoma Seed Capital Fund and the Oklahoma Angel Capital Fund II, the company said.
Also participating are NMC Health (Abu Dhabi), OCA Ventures (Chicago), Stanford University (Stanford), the Oklahoma Medical Research Foundation (Oklahoma City), Mayo Clinic, and Burns & Stowers Investments LLC (Norman, OK).
The funding round provides go-to-market capital for Progentec's CLIA laboratory and digital technologies for the management of lupus. This funding will also support new research into digital biomarkers and remote delivery of digital therapeutic programs.
Progentec is committed to improving access and health outcomes for patients in therapeutic areas with a high level of unmet need by combining clinically validated diagnostic interventions with state-of-the-art digital technologies. Through collaborations with research institutions and health practitioners around the world, Progentec is working to reduce mortality and morbidity while improving care management and service delivery for chronic health conditions.
((Comments on this story may be sent to email@example.com))